Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection

• DOI: 10.1542/peds.2023-061803
• Publication Date: 2023-06-26T08:16:39Z
• Authors: Mary T. Caserta; Sean T. O’Leary; Flor M. Munoz; Shawn L. Ralston; ; Sean T. O’Leary; James D. Campbell; Monica I. Ardura; Ritu Banerjee; Kristina A. Bryant; Mary T. Caserta; Jeffrey S. Gerber; Chandy C. John; Athena P. Kourtis; Angela Myers; Pia Pannaraj; Adam J. Ratner; José R. Romero; Samir S. Shah; Kenneth M. Zangwill; Yvonne A. Maldonado; Flor M. Munoz; Shawn L. Ralston; David W. Kimberlin; Elizabeth D. Barnett; Ruth Lynfield; Mark H. Sawyer; Henry H. Bernstein; Karen M. Farizo; Lisa M. Kafer; David Kim; Eduardo López Medina; Denee Moore; Lakshmi Panagiota...; Laura Sauvé; Jeffrey R. Starke; Jennifer Thompson; Kay M. Tomashek; Melinda Wharton; Charles R. Woods; Jennifer M. Frantz
• Keywords: Palivizumab

Guidance from the American Academy of Pediatrics (AAP) for use palivizumab prophylaxis against respiratory syncytial virus (RSV) was first published in a policy statement 1998. AAP recommendations have been updated periodically to reflect most recent literature regarding children at greatest risk severe RSV disease. Since last update 2014, which refined guidance focus on those risk, data become available seasonality circulation, incidence and factors associated with bronchiolitis hospitalizations, potential effects implementation hospitalization rates infection. This technical report summarizes review by Committee Infectious Diseases, supporting reaffirmation 2014 among infants young increased Review publications since did not support change continues endorse provided 2021 Red Book.